Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases

2018 ◽  
pp. 131-142 ◽  
Author(s):  
Shun Manabe ◽  
Kosaku Nitta ◽  
Michio Nagata
Keyword(s):  
Direct Effects ◽  
Glomerular Diseases ◽  
Immunomodulatory Agents ◽  
Immune Mediated

scholarly journals Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary

2019 ◽  
Vol 46 (7) ◽  
pp. 751-754 ◽  
Author(s):  
Kim A. Papp ◽  
Boulos Haraoui ◽  
Deepali Kumar ◽  
John K. Marshall ◽  
Robert Bissonnette ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Patient Population ◽  
Elevated Risk ◽  
Evidence Based ◽  
Executive Summary ◽  
Specific Patient ◽  
Immunomodulatory Agents ◽  
Immunization Rates ◽  
Immune Mediated ◽  
Multidisciplinary Group

The use of immunosuppressive therapies for immune-mediated disease is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases, and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive and immunomodulatory agents.

scholarly journals Transplantation of Mouse Induced Pluripotent Stem Cell-Derived Podocytes in a Mouse Model of Membranous Nephropathy Attenuates Proteinuria

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Amin Ahmadi ◽  
Reza Moghadasali ◽  
Vahid Ezzatizadeh ◽  
Zeinab Taghizadeh ◽  
Seyed Mahdi Nassiri ◽  
...  
Keyword(s):  
Pluripotent Stem Cells ◽  
Membranous Nephropathy ◽  
Therapeutic Strategy ◽  
Therapeutic Potential ◽  
Induced Pluripotent Stem Cell ◽  
Glomerular Diseases ◽  
Heavy Proteinuria ◽  
Immune Mediated ◽  
Induced Pluripotent ◽  
Shed Light

Abstract Injury to podocytes is a principle cause of initiation and progression of both immune and non-immune mediated glomerular diseases that result in proteinuria and decreased function of the kidney. Current advances in regenerative medicine shed light on the therapeutic potential of cell-based strategies for treatment of such disorders. Thus, there is hope that generation and transplantation of podocytes from induced pluripotent stem cells (iPSCs), could potentially be used as a curative treatment for glomerulonephritis caused by podocytes injury and loss. Despite several reports on the generation of iPSC-derived podocytes, there are rare reports about successful use of these cells in animal models. In this study, we first generated a model of anti-podocyte antibody-induced heavy proteinuria that resembled human membranous nephropathy and was characterized by the presence of sub-epithelial immune deposits and podocytes loss. Thereafter, we showed that transplantation of functional iPSC-derived podocytes following podocytes depletion results in recruitment of iPSC-derived podocytes within the damaged glomerulus, and leads to attenuation of proteinuria and histological alterations. These results provided evidence that application of iPSCs-derived renal cells could be a possible therapeutic strategy to favorably influence glomerular diseases outcomes.

scholarly journals Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

2013 ◽  
Vol 12 (8) ◽  
pp. 854-859 ◽  
Author(s):  
Andrea G. Kattah ◽  
Fernando C. Fervenza ◽  
Dario Roccatello
Keyword(s):  
Glomerular Diseases ◽  
Immune Mediated

scholarly journals Glomerular diseases related to HIV in Colombian population: Better outcomes with highly active antiretroviral therapy?

2020 ◽  
Vol 14 (09) ◽  
pp. 1027-1032
Author(s):  
Oscar Muñoz-Velandia ◽  
Ángel García-Peña ◽  
Javier Garzón-Herazo ◽  
Kateir Contreras-Villamizar ◽  
Martha Rodríguez-Sánchez ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Glomerular Disease ◽  
Glomerular Diseases ◽  
Highly Active ◽  
Immune Mediated ◽  
Stage Renal Disease ◽  
End Stage ◽  
Incident Cases

Introduction: End-stage renal disease (ESRD) related to HIV is becoming a leading cause of renal replacement therapy requirement is some areas of the world. Our study aims to describe the incidence and renal outcomes of HIV-associated nephropathy (HIVAN), and immune-mediated kidney disease related to HIV (HIVICK) in Colombia. Methodology: A retrospective cohort study was performed, including all HIVAN or HIVICK incident cases assessed by the infectious diseases division in a high complexity institution in Colombia, between 2004 and 2018. A longitudinal data model under the Generalized Estimating Equations (GEE) method was used to determine changes on the glomerular filtration rate (GFR) over time. Results: Within a cohort composed by 1509 HIV-infected patients, we identified 22 with HIV-associated glomerular disease. Cumulative incidence was 1.45%. At diagnosis, GFR was above 30 mL/min in 90.8% of patients, and 77.2% displayed sub-nephrotic proteinuria. Factors associated with GFR at diagnosis were: level of CD4 (Coefficient 0.113, CI 95 %: 0.046, 0.179, p < 0.01), and the inverse of the CD4/CD8 ratio. The GEE model did not demonstrate significant changes in the GFR over a 3-year period. Findings were similar when comparing GFR at diagnosis with GFR at 12 (-3.9 mL/min/1.73m2, CI 95% -7.3, 0.4, p = 0.98), 24 (-2.47 mL/min/1.73m2, CI 95% -7.0, 2.1, p=0.85), and 36 months (0.39 mL/min/1.73m2, CI 95% -4.4, 5.2, p = 0.43) of follow-up. Conclusions: Patients with glomerular disease associated with HIV have stable GFR over a 3-year period, and low rates of progression towards dialysis requirement. Differences with previous reports could be related with early diagnosis and treatment with highly active antiretroviral therapy.

scholarly journals Multiple Eruptive Dermatofibromas in Patient with Systemic Lupus Erythematosus

2019 ◽  
Vol 11 (4) ◽  
pp. 137-140
Author(s):  
Monika Janc ◽  
Gorica Ristić ◽  
Nenad Vasić ◽  
Nenad Petrov ◽  
Lidija Kandolf Sekulović
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Ulcerative Colitis ◽  
Atopic Dermatitis ◽  
Lupus Erythematosus ◽  
Biopsy Specimen ◽  
Myeloid Leukemia ◽  
Systemic Lupus ◽  
Immunomodulatory Agents ◽  
Immune Mediated ◽  
Acute Myeloid

AbstractIntroduction. Multiple eruptive dermatofibromas are described in association with different immune-mediated conditions like SLE, pemphigus, myasthenia gravis, HIV infection, organ transplantation, acute myeloid leukemia, ulcerative colitis, atopic dermatitis and immunosuppressive therapy. Case Report. A forty-five year-old woman presented at our Department with over 20 dermatofibromas on her trunk and extremities developed spontaneously over the last 3 years, out of which more than 10 lesions developed over the previous year. The patient was diagnosed with systemic lupus erythematosus before the onset of lesions and was treated with different immunomodulatory agents (corticosteroids, methotrexate, antimalarials, azathioprine, belimumab, anti IL-6 antibody). Dermoscopy of different lesions revealed different dermatoscopic patterns without pattern predominance. A biopsy specimen of one lesion confirmed the diagnosis. Conclusion. There are few cases reports describing a possible link between systemic lupus erythematosus and multiple dermatofibromas. The mechanism is still unknown but is believed to be due to the altered immunity in immune-mediated diseases.

Chemotherapeutic Agents and the Kidney

2019 ◽  
pp. 253-264 ◽  
Author(s):  
Umut Selamet ◽  
Ramy M. Hanna ◽  
Anjay Rastogi ◽  
Ala Abudayyeh
Keyword(s):  
Targeted Therapy ◽  
Anticancer Agents ◽  
Checkpoint Inhibitors ◽  
Chemotherapeutic Agents ◽  
Vascular Endothelial ◽  
Cancer Treatments ◽  
Glomerular Diseases ◽  
Immune Mediated ◽  
Renal Tubular ◽  
Endothelial Growth Factor

Chemotherapeutic agents have toxicities that extend beyond their therapeutic effect on malignant cells, and the kidneys are involved in the metabolism of these agents. Kidney toxicity delay the elimination of anticancer drugs from the body and increase the risk of systemic toxicity. Conventional chemotherapeutics generally cause direct renal tubular injury and electrolyte wasting syndromes. Newer cancer treatments include targeted therapy and immunotherapy. Targeted therapy, especially the drugs that target vascular endothelial growth factor, disrupt the crosstalk between podocytes and endothelial cells of the glomerulus resulting in a spectrum of glomerular diseases. On the other hand, immune checkpoint inhibitors release the break on the immune system and can cause immune-mediated tubulointerstitial nephritis and glomerulonephritis similar to autoimmune diseases. This chapter summarizes nephrotoxicity profiles of some of the common conventional chemotherapeutics as well as newer anticancer agents.

Sign in / Sign up

Export Citation Format

Share Document